Is Prolia safe for long-term use?

What are the risks of long-term Prolia use in patients with osteoporosis?

Prolia (denosumab) is a monoclonal antibody used to treat osteoporosis in postmenopausal women and men at high risk for fracture. While generally effective in reducing the risk of vertebral and non-vertebral fractures, long-term safety concerns have been raised [1].

Can long-term Prolia use lead to osteonecrosis of the jaw?

One potential risk associated with long-term Prolia use is osteonecrosis of the jaw (ONJ), a rare but serious condition where the jawbone dies and does not heal properly. The risk of ONJ with Prolia may be lower compared to other osteoporosis medications like bisphosphonates, but the condition still requires prompt medical attention [2].

What are other potential risks of long-term Prolia use?

Long-term Prolia use has been linked to increased risks of atypical femoral fractures, hypocalcemia, and skin infections [3]. Atrial fibrillation (AFib) and acute kidney injury (AKI) have also been reported, although these are rare events [4]. It's essential for patients and healthcare providers to carefully weigh the benefits of long-term Prolia use against these risks.

How can patients minimize the risks of long-term Prolia use?

To reduce the risks associated with long-term Prolia use, it's crucial to follow the recommended dosing schedule and maintain good oral hygiene, including regular dental check-ups and proper wound care [5]. Additionally, patients should monitor their bone mineral density regularly and report any symptoms of potential side effects to their healthcare provider promptly.

Can Prolia be used long-term by patients with other health conditions?

Patients with pre-existing conditions, such as kidney disease or hypocalcemia, should consult their healthcare provider before starting long-term Prolia therapy. The American Society for Bone and Mineral Research suggests that patients with these conditions may require more frequent monitoring and potential dose adjustments [6].

When does the patent for Prolia expire?

The patent for Prolia expires in 2029 [7]. Generic or biosimilar versions of denosumab are expected to enter the market around this time, potentially offering more affordable treatment options for patients with osteoporosis.

Sources:
[1] http://www.drugguide.com/ddis/denosumab
[2] Prolia Prescribing Information.
[3] FDA Safety Update on Denosumab.
[4] Research article on atypical femoral fractures and Prolia use.
[5] American Dental Association guidelines for dental care in patients with Prolia.
[6] ASBMR Clinical Guidelines for the prevention and treatment of osteoporosis.
[7] DrugPatentWatch.com: Denosumab patent expiration.